Intravesical BCG vs GEMDOCE in NMIBC

Inclusion Criteria: * Patient must be \> 18 years of age. * Patient must have histologically confirmed high-grade non-muscle invasive urothelial carcinoma of the bladder (HgTa, HGT1, CIS, HgTa + CIS, or HGT1 + CIS stage) on transurethral resection of bladder tumor (TURBT) obtained within 90 days prior to randomization. * Patient must have all visible papillary tumor resected by the treating urologist at the site registering the patient to this protocol prior to randomization. If the treating urologist did not perform the TURBT as outlined in Section 3.1.3, the treating urologist must perform a cystoscopy within 28 days prior to randomization to confirm the absence of visible papillary disease. * Patient must have not received prior intravesical therapy for bladder cancer, with the exception of perioperative chemotherapy at the time of TURBT. * Patients with high grade T1 disease must have undergone a restaging TURBT within 90 days prior to Step 1 randomization. NOTE: Patients with high grade T1 disease who undergo a restaging TURBT that shows no residual cancer in the restaging TURBT specimen are eligible. * Patient must not have pure squamous cell carcinoma or adenocarcinoma. * Patient must not have any component of neuroendocrine carcinoma (i.e., small cell or large cell). * Patient must not have any component of sarcomatoid, micropapillary, or plasmacytoid variant histology. * Patients with a prior or concurrent malignancy whose natural history or treatment does not hav…